Heart stent study tracks outcomes in over 2,000 chinese patients
NCT ID NCT03273023
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study looked at how well the PROMUS PREMIER stent works in everyday medical practice in China. Over 2,000 people with coronary artery disease received the stent and were followed for 12 months to track major heart problems like heart attacks or the need for another procedure. The goal was to see if the stent performs safely and effectively outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PROMUS PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System
- What this could lead to
- If successful, this study could confirm that the PROMUS PREMIER stent works well in real-world Chinese patients, supporting its continued use for treating blocked heart arteries.
- What could go wrong
- This is a post-approval observational study, not a randomized trial, so results may not prove the stent is better than other options. Risks include heart attack, need for repeat procedures, or stent-related complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?